Table 3.
Expression (%) of CD markers on the surface of freshly isolated PMBC from gastric cancer patients and healthy volunteer controls; n number of patients or volunteers tested. Only relevant results are shown. See text for a complete list of markers studied
| Surface marker | Cancer patients (mean ± SEM) | Controls (mean ± SEM) |
|---|---|---|
| CD3+ | 54 ± 5 (n=16)*** | 75 ± 2 (n=34) |
| CD4+ | 37 ± 5 (n=15)* | 47 ± 2 (n=33) |
| CD8+ | 25 ± 3 (n=15)* | 31 ± 1 (n=33) |
| CD28+ | 38 ± 5 (n=16)* | 51 ± 4 (n=29) |
| CD45+ | 90 ± 3 (n=16)* | 96 ± 1 (n=28) |
| CD86+ | 10 ± 4 (n=14)* | 3 ± 0 (n=24) |
| CD3+CD4+ | 34 ± 5 (n=14)** | 45 ± 2 (n=34) |
| CD3+CD8+ | 15 ± 2 (n=15)*** | 25 ± 1 (n=34) |
*p<0.05; **p<0.01; ***p<0.001